Jane Street’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-853,000
Closed -$20.6M – 10007
2023
Q1
$20.6M Buy
853,000
+326,000
+62% +$4.09M 0.01% 984
2022
Q4
$5.57M Buy
527,000
+112,900
+27% +$911K ﹤0.01% 2336
2022
Q3
$1.86M Buy
414,100
+63,400
+18% +$289K ﹤0.01% 4307
2022
Q2
$1.4M Sell
350,700
-20,700
-6% -$98.1K ﹤0.01% 4844
2022
Q1
$2.72M Buy
371,400
+353,300
+1,952% +$2.11M ﹤0.01% 4165
2021
Q4
$102K Sell
18,100
-7,000
-28% -$44.5K ﹤0.01% 9248
2021
Q3
$161K Sell
25,100
-70,300
-74% -$452K ﹤0.01% 9017
2021
Q2
$804K Buy
+95,400
New +$770K ﹤0.01% 6309
2020
Q4
– Sell
-79,800
Closed -$1.02M – 8328
2020
Q3
$1.02M Sell
79,800
-54,300
-40% -$686K ﹤0.01% 4063
2020
Q2
$1.89M Buy
+134,100
New +$1.69M ﹤0.01% 3141

Other funds holding PRVB

Jane Street's PRVB Position: Q2 2023 in Review

Jane Street sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 176,649 shares — an estimated $4.26M sold.

Jane Street first reported a position in PRVB in Q1 2020 and held it in 12 quarters. The position peaked at $4.26M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

  • Jane Street reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Jane Street sold 176,649 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $4.26M.
  • Jane Street first reported a position in Provention Bio, Inc. Common Stock in Q1 2020 and held it in 12 quarters.
  • Jane Street's Provention Bio, Inc. Common Stock position peaked at $4.26M in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Jane Street's 13F filing for Q2 2023, filed 14 Aug 2023.